SCHEMBL5886358

SCHEMBL5886358

CNc1ccc2nc3ccc4c(OC)cccc4c3nc2c1C(=O)OC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NQO2 P16083 1/20 0.37
MEN1 O00255 4/20 0.36
KMT2A Q03164 4/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
PLK1 P53350 1/20 0.36
CDC25B P30305 3/20 0.36
POLB P06746 4/20 0.35
PLA2G2A P14555 2/20 0.35
ADORA2A P29274 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
NCEH1 Q6PIU2 1/20 0.35
MAPT P10636 3/20 0.35
ALDH1A1 P00352 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C19 P33261 1/20 0.35
RAB9A P51151 2/20 0.34
GAA P10253 2/20 0.34
THRB P10828 1/20 0.34
BLM P54132 1/20 0.34
CASP6 P55212 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5886264 0.91 CA12 (0.42) NQO2MEN1KMT2ACDC25BPOLB
SCHEMBL5886242 0.86 IDO1 (0.40) NQO2MEN1KMT2AL3MBTL1POLB
SCHEMBL5886280 0.85 ABL1 (0.39) NQO2MEN1KMT2AL3MBTL1PLA2G2A
SCHEMBL5886260 0.81 KMT2A (0.51) NQO2MEN1KMT2APOLBPLA2G2A
SCHEMBL5886247 0.79 CA12 (0.51) NQO2MEN1KMT2AL3MBTL1CDC25B
SCHEMBL5886404 0.77 CA12 (0.45) NQO2MEN1KMT2ACDC25BPOLB
SCHEMBL5886266 0.76 CA12 (0.44) NQO2MEN1KMT2AL3MBTL1CDC25B
SCHEMBL5886271 0.74 ALDH1A1 (0.54) NQO2MEN1KMT2ACDC25BPOLB
SCHEMBL1649420 0.72 NQO2 (0.69) NQO2MEN1KMT2AL3MBTL1POLB
SCHEMBL5886455 0.71 KDM4E (0.47) NQO2MEN1KMT2ACDC25BPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7132419-B2 Pharmaceutical compounds XENOVA LIMITED (GB) 2006-11-07 US disclosed
US-20050143383-A1 Pharmaceutical compounds XENOVA LIMITED (GB) 2005-06-30 US disclosed
US-20030139409-A1 Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II XENOVA LIMITED (GB) 2003-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143383-A1 Pharmaceutical compounds CHRNA10, OPRM1, SCN10A NQO2 982/4885MEN1 2842/4885KMT2A 3473/4885
US-20030139409-A1 Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II TOP1, TOP2A, TOP2B NQO2 107/4885MEN1 4285/4885KMT2A 2184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.